Search clinical trials for: AK117

Total 50 results

Akeso

Recruiting

A Study of AK112 in Advanced Malignant Tumors

Advanced Malignant Tumors

China
Akeso

Not yet recruiting

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Akeso

Recruiting

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Akeso

Completed

A Phase 1 Dose Escalation and Expansion Study of AK117

Neoplasms Malignant

China
Akesobio Australia Pty Ltd

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Neoplasms Malignant

Australia
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
Akeso

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Akeso

Recruiting

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Advanced Malignant Tumors

China
Akeso

Recruiting

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Akeso

Terminated

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Recurrent Ovarian Carcinoma | Relapsed Ovarian Cancer

China
Akeso

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Akeso

Recruiting

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NSCLC

China
Akeso

Not yet recruiting

A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma
Akeso

Not yet recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Metastasis | Advanced or Metastatic Solid Tumors | Malignancy

Australia
Akeso

Recruiting

Study of AK119 in Subjects With Advanced Solid Tumors

Solid Tumor

China
Akeso

Not yet recruiting

A Phase I Clinical Trial of AK115 in Healthy Subjects

Healthy Volunteers
Akeso

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Akesobio Australia Pty Ltd

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

Australia
Akeso

Completed

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
Akeso

Completed

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Psoriasis

China
Akesobio Australia Pty Ltd

Completed

A Study of AK111 in Healthy Subjects

Psoriasis

New Zealand
Akeso

Active, not recruiting

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Gynecologic Cancer | Ovarian Neoplasms | Endometrial Neoplasms | Cancer Metastatic | Cervical Neoplasm

China
Akeso

Recruiting

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Akesobio Australia Pty Ltd

Completed

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Coronavirus Disease 2019 (COVID-19)

New Zealand
Akeso

Recruiting

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Non-small Cell Lung Cancer

China
Akesobio Australia Pty Ltd

Recruiting

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Neoplasms Malignant

Australia
Akeso

Active, not recruiting

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Solid Tumor, Adult

China
Akeso

Recruiting

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Harbin Medical University

Not yet recruiting

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Akeso

Recruiting

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Akeso

Recruiting

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Akeso

Recruiting

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

China
Akeso

Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Higher-risk Myelodysplastic Syndromes

United States, China
Craig L Slingluff, Jr

Terminated

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)

Melanoma

United States
Akeso

Not yet recruiting

Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Colorectal Cancer

China
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
Akeso

Active, not recruiting

AK112 in Advanced Non-Small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
Akeso

Active, not recruiting

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

SCLC, Extensive Stage

China
Hunan Province Tumor Hospital

Not yet recruiting

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (Apple)

Efficacy
Akeso

Not yet recruiting

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Resectable Non-small Cell Lung Cancer
Akeso

Recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

China
SamA Pharmaceutical Co., Ltd

Unknown

Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects

Healthy

Korea, Republic of
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Akeso

Recruiting

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Advanced Malignant Tumors

China
Summit Therapeutics
Akeso

Recruiting

Phase 3 Clinical Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

United States, Spain, China, France, Canada, Italy
Akeso

Recruiting

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer

China
Akeso

Recruiting

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NSCLC

China

3

Subscribe